Toward an understanding of the molecular genetics of prostate cancer progression

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 22, Issue 1, 2003, Pages 1-15

  Lijovic, Marijana ^a   Frauman, Albert G ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Chromosomal alterations; Genetics; Progression; Prostate cancer

Indexed keywords

CANCER GENETICS; CANCER GROWTH; CHROMOSOME ABERRATION; DISEASE COURSE; HUMAN; METASTASIS; MOLECULAR GENETICS; MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; SUPPRESSOR GENE;

CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; NEOPLASM METASTASIS; PHENOTYPE; PROSTATIC NEOPLASMS;

EID: 0037242177     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/JEnvPathToxOncol.v22.i1.10     Document Type: Review

References (160)

1. Ackerman, D. A., J. M. Barry, R. A. Wicklund, N. Olson, and B. A. Lowe: Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy,J. Urol., 150(6):1845-1850 (1993).
2. Alcaraz, A., S. Takahashi, J. A. Brown, J. F. Herath, E. J. Bergstrath, J. J. Larsonkeller, M. Lieber, and R. B. Jenkins: Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer, Cancer Res., 54(15):3998-4002 (1994).
3. Anwar, K., K. Nakakuki, T. Shiraishi, H. Naiki, R. Yatani, and M. Inuzuka: Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas, Cancer Res., 52(21):5991-5996 (1992).
4. Aprikian, A. G., A. S. Sarkis, W. R. Fair, Z. F. Zhang, Z. Fuks, and C. Cordon-Cardo: Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma,J. Urol., 151(5):1276-1280 (1994).
5. Bergerheim, U. S., K. Kunimi, V. P. Collins, and P. Ekman: Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma, Genes Chromosomes Cancer, 3(3):215-220 (1991).
6. Berry, S. J., D. S. Coffey, P. C. Walsh, and L. L. Ewing: The development of human benign prostatic hyperplasia with age, J. Urol., 132(3):474-479 (1984).
7. Birchmeier, W. and J. Behrens: Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness, Biochem. Biophys: Acta, 1198(1):11-26 (1994).
8. Bookstein, R., G. S. Bova, D. Macgrogan, A. Levy, and W. B. Isaacs: Tumour-suppressor genes in prostatic oncogenesis: a positional approach, Br. J. Urol., 79(Suppl 1):28-36 (1997).
9. Bookstein, R., D. MacGrogan, S. G. Hilsenbeck, F. Sharkey, and D. C. Allred: p53 is mutated in a subset of advanced-stage prostate cancers, Cancer Res., 53(14):3369-3373 (1993).
10. Borchers, H., F. J. Meyers, P. H. Gumerlock, S. L. Stewart, and R. W. de Vere White: nm23 gene expression in human prostatic carcinomas and benign prostatic hyperplasias: Altered expression in combined androgen blockaded carcinomas, J. Urol., 155(6):2080-2084 (1996).
11. Bostwick, D. G.: c-erbB-2 oncogene expression in prostatic intraepithelial neoplasia: mounting evidence for a precursor role, J. Natl. Cancer Inst., 86(15):1108-1110 (1994).
12. Bostwick, D. G.: Gleason grading: reply, Am. J. Surg. Pathol., 19(7):853 (1995).
13. Bostwick, D. G.: Prospective origins of prostate carcinoma: prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia, Cancer, 78(2):330-336 (1996).
14. Bostwick, D. G., A. Shan, J. Q. Qian, M. Darson, N. J. Maihle, R. B. Jenkins, and L. A. Cheng: Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma, Cancer, 83(9):1995-2002 (1995).
15. Bostwick, D. G., A. Shan, J. Qian, M. Darson, N. J. Maihle, and R. B. C. Jenkins: Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma, Cancer, 83(9):1995-2002 (1998).
16. Bouras, T. and A. G. Frauman: Expression of the prostate cancer metastasis suppressor gene KAI1 in primary prostate cancers: a biphasic relationship with tumour graded. Pathol., 188(4):382-388 (1999).
17. Bova, G. S., B. S. Carter, M. J. G. Bussemakers, M. Emi, Y. Fujiwara, N. Kyprianou, S. C. Jacobs, J. C. Robinson, J. I. Epstein, P. C. Walsh, and W. B. Isaacs: Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer, Cancer Res., 53(17):3869-3873 (1993).
18. Brewster, S. F., S. Browne, and K. W. Brown: Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma, J. Urol., 151(4):1073-1077 (1994).
19. Brooks, J. D., M. Weinstein, X. H. Lin, Y. H. Sun, S. S. Pin, G. S. Bova, J. I. Epstein, W. B. Isaacs, and W. G. Nelson: CG island methylation changes near the GSTP1 gene in prostatic intraepithelial neoplasia, Cancer Epidemiol. Biomarkers Prev., 7(6):531-536 (1998).
20. Brothman, A. R., T. M. Maxwell, J. Cui, D. A. Deubler, and X. L. Zhu: Chromosomal clues to the development of prostate tumors, Prostate, 38(4):303-312 (1999).
21. Buttyan, R., I. S. Sawczuk, M. C. Benson, J. D. Siegal, and C. A. Olsson: Enhanced expression of the c-myc proto-oncogene in high-grade human prostate cancers, Prostate, 11(4):327-337 (1987).
22. Carter, B. S., J. I. Epstein, and W. B. Isaacs: Ras gene mutations in human prostate cancer, Cancer Res., 50(21):6830-6832 (1990a).
23. Carter, B. S., C. M. Ewing, W. S. Ward, B. F. Treiger, T. W. Aalders, J. A. Schalken, J. I. Epstein, and W. B. Isaacs: Allelic loss of chromosomes 16q and 10q in human prostate cancer, Proc. Natl. Acad. Sci. USA, 87(22):8751-8755 (1990b).
24. Chen, T. H., J. R. Brody, F. E. Romantsev, J. G. Yu, A. E. Kayler, E. Voneiff, F. P. Kuhajda, and G. R. Pasernack: Structure of pp32, an acidic nuclear protein which inhibits oncogene-induced formation of transformed foci, Mol. Biol. Cell, 7(12):2045-2056 (1996).
25. Chen, W. C. and B. Obrink: Cell-cell contacts mediated by E-cadherin (uvomorulin) restrict invasive behavior of L-cells, J Cell Biol., 114(2):319-327 (1991).
26. Cheng, L., M. Nagabhushan, T. P. Pretlow, S. B. Amini, and T. G. Predow: Expression of E-cadherin in primary and metastatic prostate cancer, Am. J. Pathol., 148(5):1375-1380 (1996).
27. Cheng, L., A. Shan, J. C. Cheville, J. Qian, and D. G. Bostwick: Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res., 58(3):389-391 (1998).
28. Cheng, L., S. Y. Song, T. G. Pretlow, F. W. Abdulkarim, H. J. Kung, D. V. Dawson, W. S. Park, Y. W. Moon, M. L. Tsai, W. M. Linehan, M. R. Emmertbuck, L. A. Liotta, and Z. P. Zhuang: Evidence of independent origin of multiple tumors from patients with prostate cancer. J. Natl. Cancer Inst., 90(3):233-237 (1998b).
29. Cher, M. L., G. S. Bova, D. H. Moore, E. J. Small, P. R. Carroll, S. S. Pin, J. I. Epstein, W. B. Isaacs, and R. H.Jensen: Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping, Cancer Res., 56(13):3091-3102 (1996).
30. Cher, M. L., T. Ito, N. Weidner, P. R. Carroll, and R. H. Jensen: Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH), J. Urol., 153(1):249-254 (1995).
31. Cher, M. L., D. MacGrogan, R. Bookstein, J. A. Brown, R. B. Jenkins, and R. H. Jensen: Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer, Genes Chromosomes Cancer, 11:153-162 (1994).
32. Chi, S. G., R. W. deVere White, J. T. Muenzer, and P. H. Gumerlock: Frequent alteration of CDKN2 (p16[INK4A]/MTS1) expression in human primary prostate carcinomas, Clin. Cancer Res., 3(10):1889-1897 (1997).
33. Coetzee, L. J., L. J. Layfield, V. Hars, and D. F. Paulson: Proliferative index determination in prostatic carcinoma tissue: Is there any additional prognostic value greater than that of Gleason score, ploidy, and pathological stage? J. Urol., 157(1):214-218 (1997).
34. Coley, C. M., M. J. Barry, C. Fleming, and A. G. Mulley: Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests,The American College of Physicians, Ann. Intern. Med., 126(5):394-406 (1997).
35. Colombel, M., F. Symmans, S. Gil, K. M. O'Toole, D. Chopin, M. Benson, C. A. Olsson, S. Korsmeyer, and R. Buttyan: Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers, Am. J. Pathol., 143(2):390-400 (1993).
36. Cunningham, J. M., A. L. Shan, M. J. Wick, S. K. McDonnell, D. J. Schaid, D. J. Tester, J. Q. Qian, S. Takahashi, R. B. Jenkins, D. G. Bostwick, and S. N.Thibodeau: Allelic imbalance and microsatellite instability in prostatic adenocarcinoma, Cancer Res., 56(19):4475-4482 (1996).
37. Dhom G.: Das prostatacarzinom und die bedeutung seiner fruherkennung, Med. Unserer Zeit, 5:134-140 (1978).
38. Dinjens, W. N., M. M. van der Weiden, F. H. Schroeder, F. T. Bosman, and J. Trapman: Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer, Int J. Cancer, 56(5):630-633 (1994).
39. Doll, J. A., X. P. Zhu, J. Furman, Z. Kaleem, C. Torres, P. A. Humphrey, and H. Donis-Keller: Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis), Am. J. Pathol., 155(3):967-971 (1999).
40. Dong, J. T., P. W. Lamb, C. W. Rinker-Schaeffer J. Wukanovic,T. Ichikawa, J. T. Isaacs, and J. C. Barrett: KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2, Science, 268(5212):884-886 (1995).
41. Dong, J. T., H. Suzuki, S. S. Pin, G. S. Bova, J. A. Schalken, W. B. Isaacs, J. C. Barrett, and J. T. Isaacs: Downregulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss, Cancer Res., 56(19):4387-4390 (1996).
42. Eagle, L. R., X. Y. Yin, A. R. Brothman, B. J. Williams, N. B. Atkin, and E. V. Prochownik: Mutation of the MXI1 gene in prostate cancer, Nat. Genet., 9(3):249-255 (1995).
43. Eaton, C. L., P. Davies, and M. E. Phillips: Growth factor involvement and oncogene expression in prostatic tumours, J. Steroid Biochem., 30(1-6):341-345 (1988).
44. Effert, P. J., R. H. McCoy, P. J. Walther, and E. T. Liu: p53 gene alterations in human prostate carcinoma, J. Urol., 150(1):257-261 (1993).
45. Effert P. J., A. Neubauer, P. J. Walther, and E. T. Lie: Alterations of the p53 gene are associated with the progression of a human prostate carcinoma, J. Urol, 147(3 Pt 2):789-793 (1992).
46. Elo, J. P., P. Harkonen, A. P. Kyllonen, O. Lukkarinen, M. Poutanen, R. Vikho, and P. Vikho: Loss of heterozygosity at 16q24.1-Q24.2 is significantly associated with metastatic and aggressive behaviour of prostate cancer, Cancer Res., 57(16):3356-3359 (1997).
47. Emmertbuck, M. R., C. D. Vocke, R. O. Pozzatti, P. H. Duray, S. B. Jennings, C. D. Florence, Z. P. Zhuang, D. G. Bostwick, L. A. Liotta, and W. M. Linehan: Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia, Cancer Res., 55(14):2959-2962 (1995).
48. Epstein, J. I., G. Pizov, and P. C. Walsh: Correlation of pathologic findings with progression after radical retropubic prostatectomy, Cancer, 71(11):3582-3593 (1993).
49. Fidler, I. J.: Critical factors in the biology of human cancer metastasis: Twenty-eighth G. H. A. Clowes Memorial Award lecture, Cancer Res., 50(19):6130-6138 (1990).
50. Fishman, J. R., P. H. Gumerlock, F. J. Meyers, and R. W. de Vere White: Quantitation of nm23 expression in human prostate tissues, J. Urol., 152(1):202-207 (1994).
51. Fleming, W. H., A. Hamel, R. McDonald, E. Ramsey, N. M. Pettigrew, B. Johnston, J. G. Dodd, and R.J. Matusik: Expression of the c-myc proto-oncogene in human prostatic carcinoma and benign prostatic hyperplasia, Cancer Res., 46(3):1535-1538 (1986).
52. Fornaro, M., G. Tallini, D. O. Zheng, W. M. Flanagan, M. Manzotti, and L. R. Languino: p27(kipl) acts as a downstream effector of and is coexpressed with the beta 1C integrin in prostatic adenocarcinoma, J. Clin. Invest., 103(3):321-329 (1999).
53. Friess, H., X. Z. Guo, P. Berberat, H. U. Graber, A. Zimmermann, M. Korc, and M. W. Buchler: Reduced KAI1 expression in pancreatic cancer is associated with lymph node and distant metastases, Int. J. Cancer, 79(4):349-355 (1998).
54. Frixen, U. H., J. Behrens, M. Sachs, G. Eberle, B. Voss, A. Warda, D. Locjner, and W. Birchmeier: E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells, J. Cell Biol., 113(1):173-185 (1991).
55. Gao, A. C., W. Lou, J. T. Dong, and J. T. Isaacs: CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13, Cancer Res., 57(5):846-849 (1997).
56. Gray, I., S. Phillips, S. Lee, J. Neoptolemos, and N. Spurr: Loss of the chromosomal region 10q23-25 in prostate cancer, Cancer Res., 55(21):4800-4803 (1995).
57. Greenlee, R. T., T. Murray, S. Bolden, and P. A. Wingo: Cancer statistics, 2000, CA Cancer J. Clin., 50(1):7-33 (2000).
58. Grignon, D. J. and W. A. Sakr: Atypical adenomatous hyperplasia of the prostate: a critical review, Eur. Urol., 30(2):206-211 (1996).
59. Gumerlock, P. H., U. R. Poonamallee, F. J. Meyers, and R. W. de Vere White: Activated ras alleles in human carcinoma of the prostate are rare, Cancer Res. 51(6):1632-1637 (1991).
60. Guo, X. Z., H. Friess, F. F. Di Mola, J. M. Heinicke, M. Abou-Shady, H. U. Graber, H. U. Baer, A. Zimmermann, M. Korc, and, M. Y. Buchler: KAI1, a new metastasis suppressor gene, is reduced in metastatic hepatocellular carcinoma, Hepatology, 28(6):1481-1488 (1998).
61. Guo, Y., G. N. Sklar, A. Borkowski, and N. Kyprianou: Loss of the cyclin-dependent kinase inhibitor p27(Kipl) protein in human prostate cancer correlates with tumor grade, Clin. Cancer Res., 3(12 Pt 1):2269-2274 (1997).
62. He, W. W., P. J. Sciavolino, J. Wing, M. Augustus, P. Hudson, P. S. Meissner, R. T. Curtis, B. K. Shell, D. G. Bostwick, D. J. Tindall, E. P. Gelmann, C. Abateshen, and K. C. Carter: A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer, Genomics, 43(1):69-77 (1997).
63. Heindenberg, H. B., I. A. Sesterhenn, J. P. Gaddipati, C. M. Weghorst, G. S. Buzard, J. W. Moul, and S. Srivastava: Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer, J Urol., 154(2 Pt 1):414-421 (1995).
64. Higashiyama, M., K. Kodama, H. Yokouchi, K. Takami, M. Adachi, T. Taki, S. Ishiguro, S. Nakamori, O. Yoshie, and M. Miyake: KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis, Cancer, 83(3):466-474 (1998).
65. Hobisch, A., Z. Culig, C. Radmayr, G. Bartsch, H. Klocker, and A. Hittmair: Distant metastases from prostatic carcinoma express androgen receptor protein, Cancer Res., 55(14):3068-3072 (1995).
66. Hohbach, C. and G. Dhom: Pathology of prostatic cancer, Scand. J. Urol. Nephrol., Suppl., 55:37-47 (1980).
67. Ichikawa, T., Y. Ichikawa, and J. T. Isaacs: Genetic factors and suppression of metastatic ability of prostatic cancer, Cancer Res., 51(14):3788-3792 (1991).
68. Igawa, M., D. W. Rukstalis, T. Tanabe, and G. W. Chodak: High levels of nm23 expression are related to cell proliferation in human prostate cancer, Cancer Res., 54(5):1313-1318 (1994).
69. Igawa, M., S. Urakami, H. Shiina, T. Ishibe, T. Usui, and G.W. Chodak: Association of nm23 protein levels in human prostates with proliferating cell nuclear antigen expression at autopsy, Eur. Urol., 30(3):383-387 (1996).
70. Inazawa, J., H. Sasaki, K. Nagura, N. Kakazu,T. Abe, and T. Sasaki: Precise localization of the human gene encoding cell adhesion kinase beta (Cak-BetaJ Beta/Pyh2) to chromosome 8 at p21.1 by fluorescence in situ hybridization, Hum. Genet., 98(4):508-510 (1996).
71. Isaacs, W. B., G. S. Bova, R. A. Morton, M. J. Bussemakers, J. D. Brooks, and C. M. Ewing: Genetic alterations in prostate cancer, Cold Spring Harb. Symp. Quant. Biol., 59:653-659 (1994).
72. Isaacs, W. B., S. Bova, R. Morton, M. J. G. Bussemarkers, J. D. Brooks, and C. M. Ewing: Molecular biology of prostate cancer progression, Cancer Surv., 23:19-32 (1995).
73. Isaacs, W. B. and B. S. Carter: Genetic changes associated with prostate cancer in humans, Cancer Surv., 11:15-24 (1991).
74. Ittmann, M.: Allelic loss on chromosome 10 in prostate adenocarcinoma, Cancer Res., 56(9):2143-2147 (1996).
75. Jenkins, R. B., J. Q. Qian, H. K. Lee, H. J. Huang, K. Hirasawa, D. G. Bostwick, J. Proffitt, K. Wilber, M. M. Lieber, W. G. Liu, and D. I. Smith: A molecular cytogenetic analysis of 7q31 in prostate cancer, Cancer Res., 58(4):759-766 (1998).
76. Jenkins, R. B., J. Q. Qian, M. M. Lieber, and D. G. Bostwick: Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization, Cancer Res., 57(3):524-531 (1997).
77. Jensen, S. L., D. P. Wood Jr., E. R. Banks, M. Veron, I. Lascu, J. W. McRoberts, and V. M. Rangnekar: Increased levels of nm23-H1/nucleoside diphosphate kinase A mRNA associated with adenocarcinoma of the prostate, World J. Urol., 14(Suppl 1):S21-25 (1996).
78. Joos, S., U. S. R. Bergerheim, Y. Pan, H. Matsuyama, M. Bentz, S. Dumanoir, and P. Lichter: Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization, Genes Chromosomes Cancer, 14(4):267-276 (1995).
79. Kadkol, S. S., J. R. Brody, J. I. Epstein, F. P. Kuhajda, and G. R. Pasternack: Novel nuclear phosphoprotein pp32 is highly expressed in intermediate- and high-grade prostate cancer, Prostate, 34(3):231-237 (1998).
80. Kadkol, S. S., J. R. Brody, J. Pevsner, J. Bai, and G. R. Pasternack: Modulation of oncogenic potential by alternative gene use in human prostate cancer, Nat. Med., 5(3):275-279 (1999).
81. Kallakury, B. V., F. Yang, J. Figge, K. E. Smith, S. J. Kausik, N. J. Tacy, H. A. Fisher, R. Kaufman, H. Figge, and J. S. Ross: Decreased levels of CD44 protein and mRNA in prostate carcinoma: correlation with tumor grade and ploidy, Cancer, 78(7):1461-1469 (1996).
82. Kallioniemi, O.-P. and T. Visakorpi: Genetic basis and clonal evolution of human prostate cancer, Adv. Cancer Res., 68:225 (1996).
83. Karp, J. E., A. Chiarodo, O. Brawley, and G. J. Kelloff: Prostate cancer prevention: investigational approaches and opportunities, Cancer Res., 56(24):5547-5556 (1996).
84. Kawana, Y., A. Komiya, T. Ueda, N. Nihei, H. Kuramochi, H. Suzuki, R. Yatani, T. Imai, J. T. Dong, T. Imai, O. Yoshie, J. C. Barrett, J. T. Isaacs, J. Shimazaki, H. Ito, and T. Ichikawa: Location of KAI1 on the short arm of human chromosome 11 and frequency of allelic loss in advanced human prostate cancer, Prostate, 32(3):205-213 (1997).
85. Klo, J. P., P. Harkonen, A. P. Kyllonen, et al.: Loss of heterozygosity at 16q24.1-Q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer, Cancer Res., 57(6):3356 (1997).
86. Koivisto, P., J. Kononen, C. Palmberg, T. Tammela, E. Hyytinen, J. Isola, J. Trapman, K. Cleutjens, A. Noordzij, T. Visakorpi, and O. P. Kallioniemi: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer, Cancer Res., 57(2):314-319 (1997).
87. Kojima, M., P. Troncoso, and R. J. Babaian: Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error, Urology, 45(5):807-812 (1995).
88. Komiya, A., H. Suzuki, T. Ueda, M. Emi, H. Ito, and J. Shimazaki: Allelic losses at loci on chromosome 10 are associated with metastasis and progression of human prostate cancer, Genes Chromosomes Cancer, 17(4):245-253 (1996).
89. Konishi, N., T. Enomoto, G. Buzard, M. Oshima, J. M. Ward, and J. M. Rice: K-ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men, Cancer, 69(9):2293-2299 (1992).
90. Konishi, N., Y. Hiasa, H. Matsuda, M. Tao, T. Tsuzuki, I. Hayashi, Y. Kitahori, T. Shiraishi, R. Yatani, J. Shimazaki, and J. C. Lin: Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma, Am. J. Pathol., 147(4):1112-1122 (1995).
91. Konishi, N., Y. Hiasa, T. Tsuzuki, M. Tao, T. Enomoto, and G. J. Miller: Comparison of ras activation in prostate carcinoma in Japanese and American men, Prostate, 30(1):53-57 (1997).
92. Korsmeyer, S. J.: Bcl-2 initiates a new category of oncogenes: regulators of cell death, Blood, 80(4):879-886 (1992).
93. Krajewska, M., S. Krajewski, J. I. Epstein, A. Shabaik, J. Sauvageot, K. Song, S. Kitada, and J. C. Reed: Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers, Am. J. Pathol., 148(5):1567-1576 (1996).
94. Lacombe, L., I. Orlow, V. E. Reuter, W. R. Fair, G. Dalbagni, Z. F. Zhang, and C. Cordoncardo: Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer, Int. J. Cancer, 69(2):110-113 (1996).
95. Land, H., L. F. Parada, and R. A. Weinberg: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes, Nature, 304(5927):596-602 (1993).
96. Latil, A. and R. Lidereau Genetic aspects of prostate cancer, Virchows Arch., 432(5):389-406 (1998).
97. Li, J., C. Yen, D. Liaw, K. Podsypanina, S. Bose, S. I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S. H. Bigner, B. C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M. H. Wigler, and R. Parsons: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, Science, 275(5308):1943-1947 (1997).
98. MacGrogan, D. and R. Bookstein, Tumour suppressor genes in prostate cancer, Semin. Cancer Biol., 8(1):11-19 (1997).
99. Macoska, J. A., M. A. Micale, W. A. Sakr, P. D. Benson, and S. R. Wolman: Extensive genetic alterations in prostate cancer revealed by dual PCR and FISH analysis, Genes Chromosomes Cancer, 8(2):88-97 (1993).
100. Macoska, J. A., I. J. Powell, W. Sakr, and M. A. Lane: Loss of the 17p chromosomal region in a metastatic carcinoma of the prostate, J. Urol., 147(4):1142-1146 (1992).
101. Macoska, J. A., T. M. Trybus, P. D. Benson, W. A. Sakr, D. J. Grignon, K. D. Wojno, T. Pietruk, and I. J. Powell: Evidence for three tumor suppressor gene loci on chromosome 8p in human prostrate cancer, Cancer Res., 55(22):5390-5395 (1995).
102. Macoska, J. A., T. M. Trybus, W. A. Sakr, M. C. Wolf, P. D. Benson, I. J. Powell, and J. E. Pontes: Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer, Cancer Res., 54(14):3824-3830 (1994).
103. Malek, S. N., A. I. Katumuluwa, and G. R. Pasternack: Identification and preliminary characterization of two related proliferation-associated nuclear phosphoproteins, J. Biol. Chem., 265(22):13400-13409 (1990).
104. Matusik, R. J., W. H. Fleming, A. Hamel, T. G. Westenbrink, B. Hrabarchuk, R. MacDonald, E. Ramsey, J. G. Gertner, N. M. Pettigrew, B. Johnston, T. G. Alam, and J. G. Dodd: Expression of the c-myc proto-oncogene in prostatic tissue, Prog. Clin. Biol. Res., 239:91-112 (1987).
105. McDonnell, T. J., P. Tronosco, S. M. Brisbay, C. Logothetis, L.W. Chung, J. T. Hseih, S. M.Tu, and M. L. Campbell: Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer, Cancer Res., 52(24):6940-6944 (1992).
106. Mirchandani, D., J. Zheng, G. J. Miller, A. K. Ghosh, D. K. Shibata, R. J. Cote, and P. Roy-Burman: Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer, Am. J. Pathol., 147(1):92-101 (1995).
107. Montironi, R., D. G. Bostwick, H. Bonkhoff, A. T. K. Cockett, B. Helpap, P. Troncoso, and D. Waters: Workgroup 1: Origins of prostate cancer, Cancer, 78(2):362-365 (1996).
108. Morita, T., N. Shinohara, and A. Tokue: Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma, Br. J. Urol., 74(4):416-421 (1994).
109. Morton, R. A., C. M. Ewing, A. Nagafuchi, S. Tsukita, and W. B. Isaacs: Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells, Cancer Res., 53(15):3585-3590 (1993).
110. Moul, J. W., P. A. Friedrichs, R. S. Lance, S. M. Theune, and E. H. Chang: Infrequent ras oncogene mutations in human prostate cancer, Prostate, 20(4):327-338 (1992).
111. Myers, M. P., J. P. Stolarov, C. Eng,J. Li, S. I. Wang, M. H. Wigler, R. Parsons, and N. K. Tonks: PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase, Proc. Natl. Acad. Sci. USA, 94(17):9052-9057 (1997).
112. Myers, R. B., S. Srivastava, D. K. Oelschlager, D. Brown, and W. E. Grizzle: Expression of nm23-H1 in prostatic intraepithelial neoplasia and adenocarcinoma, Hum. Pathol., 27(10):1021-1024 (1996).
113. Myers, R. B., S. Srivastava, K. K. Oelschlager, and W. E. Grizzle: Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma, J. Natl. Cancer Inst., 86(15):1140-1145 (1994).
114. Nagabhushan, M., T. G. Pretlow, Y.-J. Guo, S. B. Amini, T. P. Pretlow, and M.-S. Sy: Altered expression of CD44 in human prostate cancer during progression, Am. J. Clin. Pathol., 106(5):647-651 (1996).
115. Narayan, P., P. Jajodia, R. Stein, and E. A. Tanagho: A comparison of fine needle aspiration and core biopsy in diagnosis and preoperative grading of prostate cancer, J. Urol., 141(3):560-563 (1989).
116. Navone, N. M., P. Tronosco, L. L. Pisters, T. L. Goodrow, J. L. Palmer, W. W. Nichols, A. C. von Eschenbach, and C. J. Conti: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma, J. Nat. Cancer Inst. 85(20):1657-1669 (1993).
117. Nupponen, N. and T. Visakorpi: Molecular biology of progression of prostate cancer, Eur. Urol., 35(5-6):351-354 (1999).
118. Nupponen, N. N., L. Kakkola, P. Koivisto, and T. Visakorpi: Genetic alterations in hormone-refractory recurrent prostate carcinomas, Am. J. Pathol., 153(1):141-148 (1998).
119. Oesterling, J. E., C. B. Brendler, J. I. Epstein, A. W. Kimball, Jr., and P. C. Walsh: Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate, J. Urol., 138(1):92-98 (1987).
120. Ow, K., W. Delprado, R. Fisher, J. Barrett, Y. Yu, P. Jackson, and P. J. Russell: Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer, J. Pathol., 191(1):39-47 (2000).
121. Phillips, M. E., M. A. Ferro, P. J. Smith, and P. Davies: Intranuclear androgen receptor deployment and proto-oncogene expression in human diseased prostate, Urol. Int. 42(2):115-119 (1987).
122. Pienta, K. J., J. A. Goodson, and P. S. Esper: Epidemiology of prostate cancer: molecular and environmental clues, Urology, 48(5):676-683 (1996).
123. Qian, J. Q., D. G. Bostwick, S. Takahashi, T. J. Borell, J. F. Herath, M. M. Lieber, and R. B. Jenkins: Chromosomal anomalies in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization, Cancer Res., 55(22):5408-5414 (1995).
124. Qian J. Q., R. B. Jenkins, and D. G. Bostwick: Potential markers of aggressiveness in prostatic intraepithelial neoplasia detected by fluorescence in situ hybridization, Eur. Urol., 30(2):177-184 (1996).
125. Qian, J. Q., R. B. Jenkins, and D. G. Bostwick: Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization, Eur. Urol., 35(5-6):479-483 (1999).
126. Raffo, A. J., H. Perlman, M. W. Chen, M. L. Day, J. S. Streitman, and R. Buttyan: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo, Cancer Res., 55(19):4438-4445 (1995).
127. Richmond, P. J., A. J. Karayiannakis, A. Nagafuchi, A. V. Kaisary, and M. Pignatelli: Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival, Cancer Res., 57(5):3189-3193 (1997).
128. Ruijter, E., C. Van de Kaa, G. Miller, D. Ruiter, F. Debruyne, and J. Schalken: Molecular genetics and epidemiology of prostate carcinoma, Endocrine Rev., 20(1):22-45 (1999).
129. Ruizeveld de Winter, J. A., P. J. Janssen, H. M. Sleddens, M. C. Verleun-Mooijman, J. Trapman,A. O. Brinkmann, A. B. Santerse, F. H. Schroder, and T. H. van der Kwasi: Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer, Am. J. Pathol., 144(4):735-746 (1994).
130. Russell, P.J., P. L. Molloy, and G.W. Both: Gene therapy for prostate cancer, Today's Life Sci. (June), 20-27 (1997).
131. Sakr, W. A., J. A. Macoska, P. Benson, D.J. Grignon, S. R. Wolman, J. E. Pontes, and J. D. Crissman: Allelic loss in locally metastatic, multisampled prostate cancer, Cancer Res., 54(12):3273-3277 (1994).
132. Shi, X. B., S. M. Bodner, R. W. de Vere White, and P. H. Gumerlock: Identification of p53 mutations in archival prostate tumors: sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay, Diagn. Mol. Pathol., 5(4):271-278 (1996).
133. Sledge, G. W., Jr., M. Qulali, R. Goulet, E. A. Bore, and R. Fife: Effect of matrid metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice, J. Natl. Cancer Inst., 87(20):1546-1550 (1995).
134. Stamey, T. A., F. S. Freiha, J. E. McNeal, E. A. Redwine, A. S. Whittemore, and H. P. Schmid: Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer, Cancer, 71(3 Suppl):933-938 (1993).
135. Steck, P. A., M. A. Pershouse, S. A. Jasser, W. K. A. Yung, H. Lin, A. H. Ligon, L. A. Langford, M. L. Baumgard, T. Hattier, T. Davis, C. Frye, R. Hu, B. Swedlund, D. H. F. Teng, and S. V. Tavtigian: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers, Nat. Genet., 15(4):356-362 (1997).
136. Stone, N. N., R. G. Stock, and P. Unger: Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate, J. Urol., 154(4):1392-1396 (1995).
137. Suzuki, H., D. Freije, D. R. Nusskern, K. Okami,P. Cairns, D. Sidransky, W. B. Isaacs, and G. S. Bova: Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues, Cancer Res., 58(2):204-209 (1998).
138. Suzuki, H., A. Komiya, M. Emi, H. Kuramochi, T. Shiraishi, R. Yatani, and J. Shimazaki: Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers, Genes Chromosomes Cancer, 17(4):225-233 (1996).
139. Takahashi, S., A. Alcaraz, J. A. Brown, T. J. Borell, J. F. Herath, E. J. Bergstralh, M. M. Lieber, and R. B. Jenkins: Aneusomies of chromosomes 8 and Y detected by fluorescence in situ hybridization are prognostic markers for pathological stage C (pt3N0M0) prostate carcinoma, Clin. Cancer Res., 2(1):137-145 (1996).
140. Takahashi, S., J. Q. Qian, J. A. Brown, A. Alcaraz, D. G. Bostwick, M. M. Lieber, and R. B. Jenkins: Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridization in needle biopsies, Cancer Res., 54(13):3574-3579 (1994).
141. Taplin, M. E., G. J. Bubley, T. D. Shuster, M. E. Frantz, A. E. Spooner, G. K. Ogata, H. N. Keer, and S. P. Balk: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer, N. Engl. J. Med., 332(21):1393-1398 (1995).
142. Trybus, T., A. Burgess, K. Wojno, T. Glover, and J. Macoska: Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer, Cancer Res., 56(10):2263-2267 (1996).
143. Ueda, T., T. Ichikawa, J. Tamaru, A. Mikata, K. Akakura, S. Akimoto, T. Imai, O. Yoshie, T. Shiraishi, R. Yatani, H. Ito, and J. Shimazaki: Expression of the KAI1 protein in benign prostatic hyperplasia and prostate cancer, Am. J. Pathol., 149(5):1435-1440 (1996).
144. Umbas, R., W. B. Isaacs, P. P. Bringuier, H. E. Schaafsma, H. F. M. Karthaus, G. O. Oosterhof, F. M. Dejbruyne, and J. A. Schalken: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer, Cancer Res., 54(14):3929-3933 (1994).
145. Umbas, R., J. A. Schalken, T. W. Aalders, B. S. Carter, H. F. Karthaus, H. F. Schaafsma, F. M. Debruyne, and W. B. Isaacs: Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer, Cancer Res., 52(18):5104-5109 (1992).
146. van Veldhuizen, P. J., R. Sadasivan, F. Garcia, M. S. Austenfeld, and R. L. Stephens: Mutant p53 expression in prostate carcinoma, Prostate, 22(1):23-30 (1993).
147. Visakorpi, T., E. Hyytinen, P. Koivisto, M. Tanner, R. Keinanen, C. Palmberg, A. Palotie, T. Tammela, J. Isola, and O. P. Kallioniemi: In vivo amplification of the androgen receptor gene and progression of human prostate cancer, Nat. Genet., 9(4):401-406 (1995a).
148. Visakorpi, T., A. H. Kollioniemi, A. C. Syvanen, E. R. Hyytinen, R. Karhu, T. Tammela, J. J. Isola, and O. P. Kallioniemi: Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization, Cancer Res., 55(2):342-347 (1995b).
149. Vleminckx, K., L. Vakaet, Jr., M. Mareel, W. Fiers, and F. van Roy: Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role, Cell, 66(1):107-119 (1991).
150. Vocke, C. D., R. O. Pozzatti, D. G. Bostwick, C. D. Florence, S. B. Jennings, S. E. Strup, P. H. Duray, L. A. Liotta, M. R. Emmertbuck, and W. M. Linehan: Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21, Cancer Res., 56(10):2411-2416 (1996).
151. Voeller, H. J., L.Y. Sugars,T. Pretlow, and E. P. Gelmann: p53 oncogene mutations in human prostate cancer specimens, J. Urol., 151(2):492-495 (1994).
152. Walensky, L. D., D. S. Coffey, T. H. Chen, T. C. Wu, and G. R. Pasternack: A novel M(r) 32,000 nuclear phosphoprotein is selectively expressed in cells competent for self-renewal, Cancer Res. 53(19):4720-4726 (1993).
153. Wales, M. M., M. A. Biel, W. Eldeiry, B. D. Nelkin, P. Issa, W. K. Cavenee, S. J. Kuerbitz, and S. B. Baylin: p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3, Nat. Med., 1(6):570-577 (1995).
154. Wang, R. Y., P. Troncoso, J. L. Palmer, A. K. Elnaggar, and J. C. Liang: Trisomy 7 by dual-color fluorescence in situ hybridization: a potential biological marker for prostate cancer progression, Clin. Cancer Res., 2(9):1553-1558 (1996).
155. Wang, S. I., R. Parsons, and M. Ittmann: Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas, Clin. Cancer Res., 4(3):811-815 (1998).
156. Wingo, P. A., S. Landis, and L. A. G. Ries: An adjustment to the 1997 estimate for new prostate cancer cases, CA Cancer J. Clin., 47(4):239-242 (1997).
157. Wolman, S. R., J. A. Macoska, M. A. Micale, and W. A. Sakr: An approach to definition of genetic alterations in prostate cancer, Diagn. Mol. Pathol., 1(3):192-199 (1992).
158. Zagars, G. K., A. Pollack, and A. C. Voneschenbach: Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era, Cancer, 79(7):1370-1380 (1997).
159. Zenklusen, J. C., J. C. Thompson, P. Troncoso, J. Kagan, and C.J. Conti: Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1, Cancer Res., 54(24):6370-6373 (1994).
160. Zhau, H. J., D. S. Wan, J. Zhou, G. J. Miller, and A. C. von Eschenbach: Expression of c-erb B-2/neu protooncogene in human prostatic cancer tissues and cell lines, Mol. Carcinogen, 5(4):320-327 (1992).